Increased activity of the NLRP3 inflammasome in immune cells in the blood is a potential biomarker of primary progressive multiple sclerosis (PPMS), according to a new study published in Brain. The finding could also provide new targets for therapeutic intervention.
“Prognostic molecular biomarkers for MS are lacking”, explains Manuel Comabella, who led the study alongside Sunny Malhotra. “Biomarkers are particularly needed for the progressive form of the disease, for which there is no effective therapy.”
The researchers performed RNA sequencing on peripheral blood mononuclear cells and found that the expression of multiple pro-inflammatory genes, including those encoding IL-1β and NLRP3, was higher in participants with PPMS than in participants with other forms of MS and in healthy controls. This finding was replicated with real-time PCR in a second cohort. NLRP3 forms a protein complex called an inflammasome, which mediates secretion of IL-1β.
During a follow-up period, participants with PPMS who had high IL-1β mRNA levels needed walking assistance an average of 11 years earlier than their counterparts with low IL-1β mRNA levels, suggesting that IL-1β expression is a prognostic marker. IL-1β expression was not associated with disease progression in participants with other forms of MS, indicating that the marker could be specific for PPMS.
The authors suggest that this finding could inform the search for new MS therapies. “At present, we are working on the identification of specific NLRP3 inflammasome inhibitors that totally suppress IL-1β secretion and have the potential to become effective treatments by preventing disease progression in patients with PPMS,” concludes Comabella.
References
Original article
Malhotra, S. et al. NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain https://doi.org/10.1093/brain/awaa084 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lemprière, S. NLRP3 inflammasome activity as biomarker for primary progressive multiple sclerosis. Nat Rev Neurol 16, 350 (2020). https://doi.org/10.1038/s41582-020-0366-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-020-0366-y
This article is cited by
-
Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-κB/NLRP3 pathways in inflammatory endothelial cells
Journal of Nanobiotechnology (2023)
-
Single-cell analysis reveals inflammatory interactions driving macular degeneration
Nature Communications (2023)
-
Highly sensitive Curcumin-conjugated nanotheranostic platform for detecting amyloid-beta plaques by magnetic resonance imaging and reversing cognitive deficits of Alzheimer's disease via NLRP3-inhibition
Journal of Nanobiotechnology (2022)
-
Neuronal accumulation of peroxidated lipids promotes demyelination and neurodegeneration through the activation of the microglial NLRP3 inflammasome
Nature Aging (2021)
-
Metformin improves depressive-like symptoms in mice via inhibition of peripheral and central NF-κB-NLRP3 inflammation activation
Experimental Brain Research (2020)